Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma

Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma

Abstract Background This study assessed the safety, preliminary antitumor activity, and pharmacokinetics of HR070803 (a novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcino...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiang Xu, Xue Zhao, Xianze Wang, Ruizhe Zhu, Yuejuan Cheng, Tao Xia, Heshui Wu, He Tian, Yuping Sun, Mingjun Zhang, Chuntao Gao, Deliang Fu, Xiaojie Wu, Tongsen Zheng, Xiaoyu Yin, Yili Chen, Xiaobing Chen, Zhihua Li, Rufu Chen, Xue Yang, Huan Wang, Quanren Wang, Xiaohong Han, Wenming Wu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Medicine
Subjects:
HR070803
liposomal irinotecan
untreated metastatic PDAC
phase 1 trial
RP2D
Online Access:https://doi.org/10.1186/s12916-025-04234-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-025-04234-4

Similar Items